Glucarpidase Market Industry Analysis, Size, Share, Trends and Forecast 2034
Glucarpidase , also known by the brand name Voraxaze, is an enzyme used to treat toxic levels of methotrexate in the blood, a situation that can occur in patients with impaired renal function. Methotrexate is a chemotherapy agent and immune system suppressant commonly used to treat cancer and autoimmune diseases. When methotrexate levels become too high, it can cause severe or life-threatening toxicities, and glucarpidase acts by breaking down methotrexate into inactive, non-toxic components. The Glucarpidase market is projected to rise at a compound annual growth rate (CAGR) of xx from 2024 to 2034, when it is anticipated to reach USD xx billion, based on an average growth pattern. The market is expected to be valued USD x billion in 2024. The primary reasons propelling the global glucarpidase market are increasing cancer rates that necessitate high-dose methotrexate therapy, expanding awareness and diagnosis of methotrexate toxicity, and advancements in enzyme production...